The disconnect between individual-level and population-level HIV prevention benefits of antiretroviral treatment
In 2019, the HIV pandemic is growing and soon over 40 million people will be living with HIV. Effective population-based approaches to decrease HIV incidence are as relevant as ever given modest reductions observed over the past decade. Treatment as prevention is often heralded as the path to improve HIV outcomes and to reduce HIV incidence.
In this report, UNAIDS is announcing that 18.2 million people now have access to HIV treatment. The Fast-Track response is working. Increasing treatment coverage is reducing AIDS-related deaths among adults and children. But the life-cycle approach has to include more than just treatment. Tuberculosis (TB) remains among the commonest causes of illness and death among people living with HIV of all ages, causing about one third of AIDS-related deaths in 2015. These deaths could and should have been prevented.
UNAIDS announces 18.2 million people on antiretroviral therapy, but warns that 15–24 years of age is a highly dangerous time for young women
UNAIDS warns that after significant reductions, declines in new HIV infections among adults have stalled and are rising in some regions
Efforts to reach fewer than 500 000 new HIV infections by 2020 are off track. This simple conclusion sits atop a complex and diverse global tapestry.
This year’s AVAC Report takes on one of the most urgent issues facing biomedical HIV prevention today: gaps in the type and quality of data collected on prevention for HIV-negative people. Globally, the number of new HIV infections is not declining. In the places where gains have been made, continued progress is not guaranteed. Fixing core problems with how prevention data are collected and reported is key to slowing the rate of new cases of HIV.